BTTC and CERN are now part of large, multi-institutional networks that focus on delivering clinical trial options for malignant gliomas around the country, supported by molecular profiling, patient outcomes studies, and innovative drug discovery among other goals.Īdditionally, there are various research programs within NOB, namely Cancer Metabolism, Molecular and Cancer Cell Biology, Cancer Stem Cell Biology, Immunology, Translational Research, and Patient Outcomes, each led by an investigator with a specific area of expertise.
His role in founding and establishing both the Brain Tumor Trials Collaborative (BTTC), of which NOB is the lead center, and the Collaborative Ependymoma Research Network (CERN) have been crucial foundational pillars to establish a hypothesis-driven research program that then supports pre-clinical and clinical studies to advance therapies for rare cancers. Gilbert’s focus for the branch has been to explore precision medicine and immunotherapy options by utilizing computational, biological and clinical trial approaches stemming from a strong basic research program. Since heterogeneity is a hallmark of brain tumors, Dr. Gilbert’s vision is to not only find effective treatment for brain tumors as an area of unmet need, but also to establish paradigms of clinical and translational investigation that can then be utilized worldwide to help other physicians make a collective impact in neuro-oncology. Gilbert has established a robust research program at the Neuro-Oncology Branch with a multidisciplinary research group and accomplished clinicians that can improve treatment and patient outcomes. As immunotherapy and precision medicine begin to become relevant in the field, Dr. Advances in therapeutic approaches for patients with primary brain tumors has struggled to keep pace over the last few decades, as surgery, radiation and chemotherapy remain the staples of clinical care.
0 kommentar(er)
